The vaccine and biotechnology company Abera Bioscience reported, as expected, no revenue during the first quarter. The operating loss increased.Operating profit/loss was SEK -5.8 million (0). Profit/loss before and after tax was SEK -5.8 million (0.0). Earnings per share amounted to SEK -0.29 (0.00). Cash and cash equivalents amounted to SEK 26 million (5.5) on 31 March."The year has started with high activity throughout the organization, where we are simultaneously driving the development of our pneumococcal vaccine toward clinical phase and accelerating the preclinical work within pandemic influenza. Taken together, this strengthens our position as a company with both short-term milestones and long-term potential within next-generation vaccines," says CEO Maria Alriksson in the interim report."In summary, we have taken important steps forward during the quarter. With GMP production in its final stage, preparations for the clinical phase in full swing, and a growing preclinical data package within influenza, we are well prepared for the upcoming milestones." Abera Bioscience, SEK millionQ1-2026Q1-2025ChangeNet sales0.00.0Operating profit/loss-5.80Profit/loss before tax-5.80.0Net profit/loss-5.80.0Earnings per share, SEK-0.290.00Cash and cash equivalents265.5